Literature DB >> 16720978

Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.

Shuzo Matsushita1, Soichiro Takahama, Junji Shibata, Tetsuya Kimura, Koichi Shiozaki, Yasuyuki Eda, Atsushi Koito, Toshio Murakami, Kazuhisa Yoshimura.   

Abstract

By immunizing mice sequentially with six different V3 peptides we obtained a murine monoclonal antibody (MAb) C25, and its humanized counterpart KD-247. The MAb recognizes the sequence IGPGRA at the tip of the V3 loop and displays broad neutralizing activity against a variety of HIV-1 isolates. KD-247 was tested in an ex vivo neutralization assay to determine its capability to contain the spread of a quasi species population of clade B HIV-1 derived from two patients. The epitope of KD-247 was generally matching with the V3 sequences of various clones isolated from plasma and peripheral blood mononuclear cells (PBMC) of two patients. Complete or strong inhibition of viral replication was observed when the patients' PBMC were cultured with a high concentration of KD-247. Some neutralization escape variants, which had mutations in the V3 or outside of the V3 loop, emerged only at a low concentration of the MAb. These results suggest that KD-247 could be a good candidate for immunotherapy against HIV-1 in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16720978

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN: 1093-2607


  6 in total

1.  Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.

Authors:  Karen A Kirby; Yee Tsuey Ong; Atsuko Hachiya; Thomas G Laughlin; Leslie A Chiang; Yun Pan; Jennifer L Moran; Bruno Marchand; Kamalendra Singh; Fabio Gallazzi; Thomas P Quinn; Kazuhisa Yoshimura; Toshio Murakami; Shuzo Matsushita; Stefan G Sarafianos
Journal:  FASEB J       Date:  2014-10-28       Impact factor: 5.191

2.  Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 gp120 V3 loop.

Authors:  Y T Ong; K A Kirby; A Hachiya; L A Chiang; B Marchand; K Yoshimura; T Murakami; K Singh; S Matsushita; S G Sarafianos
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2012-12-22       Impact factor: 1.770

3.  Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms.

Authors:  Adeyemi O Adedeji; William Severson; Colleen Jonsson; Kamalendra Singh; Susan R Weiss; Stefan G Sarafianos
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

4.  Molecular Antiretroviral Resistance Markers of Human Immunodeficiency Virus-1 of CRF01_AE Subtype in Bali, Indonesia.

Authors:  Nyoman Sri Budayanti; Tuti Parwati Merati; Budiman Bela; Gusti Ngurah Mahardika
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

Review 5.  Antiviral drugs specific for coronaviruses in preclinical development.

Authors:  Adeyemi O Adedeji; Stefan G Sarafianos
Journal:  Curr Opin Virol       Date:  2014-07-02       Impact factor: 7.090

6.  An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.

Authors:  Xin Chen; Liu Xue; Xiao Ding; Jing Zhang; Lei Jiang; Sha Liu; Hongjia Hou; Bin Jiang; Liang Cheng; Qing Zhu; Lijie Zhang; Xiaosui Zhou; Jie Ma; Qi Liu; Yucheng Li; Zhiying Ren; Beibei Jiang; Xiaomin Song; Jing Song; Wei Jin; Min Wei; Zhirong Shen; Xuesong Liu; Lai Wang; Kang Li; Tong Zhang
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.